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OBJECTIVES We sought to test the postulate that biventricular pacing diminishes the need for appropriate
tachycardia therapy. We reviewed the frequency of therapy in patients, serving as their own
controls, who were enrolled in the Ventak CHF (congestive heart failure) biventricular pacing
study.
BACKGROUND It is well established that both acute and chronic CHF contribute to the need for
tachyarrhythmia therapy in recipients of an automatic implantable cardioverter defibrillator
(ICD). Synchronized biventricular (BV) pacing is a new and promising therapy for
symptomatic improvement of CHF in selected patients (low ejection fraction, intraventricular
conduction delay). We postulate that this pacing therapy will diminish the need for
tachyarrhythmia therapy.
METHODS Participants in the Ventak CHF trial received a triple-chamber biventricular ICD with a
transvenous right ventricular lead and a left ventricular (LV) lead placed via thoracotomy. Of
54 patients enrolled in the Ventak CHF trial, 32 could be analyzed, with each completing
three blinded months programmed to BV VDD pacing and a second randomly assigned
three-month period of no pacing.
RESULTS Of the 32 patients, 13 (41%) received appropriate therapy for a ventricular tachyarrhythmia
at least once in the six-month monitoring period postimplant. Five patients (16%) had at least
one tachyarrhythmic episode while programmed to BV pacing, whereas 11 (34%) had at least
one episode while programmed to no pacing. Three patients (9%) received therapy in both
pacing periods, two with BV pacing only. The decrease in necessary tachycardia therapy
during the BV pacing period was statistically significant (p 5 0.035).
CONCLUSIONS In patients with standard ICD indications who also have CHF, LV dysfunction, and an
intraventricular conduction delay, ICD therapy is less common with BV pacing. The
mechanism for this improvement is unclear but may be related to hemodynamic improvement
in CHF. Although BV pacing does not obviate the need for an ICD, it does diminish the
need for appropriate tachyarrhythmia therapy in selected patients. (J Am Coll Cardiol 2000;
36:824–7) © 2000 by the American College of Cardiology
Ventricular arrhythmias and resultant implantable cardio-
verter defibrillator (ICD) therapy are more common in
patients with congestive heart failure (HF) (1). This corre-
lation occurs both when an individual patient has an
exacerbation of HF as well as across patient populations.
Despite similar indications for an ICD, patients are more
likely to receive an ICD shock if they have a lower ejection
fraction or a higher New York Heart Association (NYHA)
functional class (2,3). Conversely, treatment of HF is
associated with a lower incidence of ICD therapy delivery.
See page 828
Early data suggest that, in selected patients, biventricular
(BV) pacing is an effective treatment for symptomatic
HF—though this is still being validated (4,5). The mech-
anism involved in this treatment is still under study. Ever
since its inception, it has been recognized that BV pacing
for HF may be complementary to ICD therapy for life-
threatening ventricular arrhythmias. However, it is possible
that the two treatments may have synergistic benefits.
Specifically, BV pacing therapy for HF may impact the need
for ICD therapy for tachyarrhythmias, either as a proar-
rhythmic or antiarrhythmic factor. Our postulate is that
electrical treatment of HF utilizing BV pacing will reduce
the need for ICD therapy.
METHODS
Trial design. Patients evaluated were all participants in the
Ventak CHF trial. The study is an as-yet-unpublished
blinded, randomized comparison of BV pacing with “no
pacing” (see protocol below) in candidates for an ICD.
Participants must have symptomatic HF (NYHA functional
class II or greater), an ejection fraction below 0.35 and a
QRS width of $120 ms (6). For this study, a transvenous
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system for left ventricular (LV) pacing was not available. All
LV leads were placed via thoracotomy at a mid- or apical
site on the anterior or lateral LV epicardium (see Fig. 1).
Although study patients had an intraventricular conduction
delay, no patient was enrolled who had a requirement for a
permanent pacemaker or who had chronic atrial fibrillation.
After obtaining informed consent, unipolar epicardial
pacing leads were placed via thoracotomy and tunneled to a
left subclavicular generator (Fig. 1). Traditional transvenous
dual chamber ICD leads were placed via the left subclavian
venous system and also attached to the generator, which was
implanted either subcutaneously or submuscularly in the left
chest similar to standard transvenous ICD implantation
techniques (7).
Protocol. After a one-month postoperative recovery pe-
riod, patients were randomized to receive a three-month
period of either atrial synchronous ventricular pacing
(VDD) or no pacing, which actually comprised BV VVI
pacing at 40 ppm maintained for safety reasons. The pacing
mode was blinded to the patient. A second three-month
period followed with the pacemaker in the alternative
therapy mode. At the conclusion of each treatment period,
patients underwent ICD interrogation, including evaluation
of episode frequency, stored electrograms, histograms, per-
cent paced, and other parameters.
Statistical analysis. All tests were two-sided, and p values
below 0.05 were considered significant. Continuous paired
variables were compared with a paired Student t-test.
Statistical tests were performed with Statview 5.0 for
Windows (SAS Institute, Cary, North Carolina). Period
effects, carryover effects, and other interactions between
treatment and period were tested using the methodology
described by Pocock (8). Descriptive variables are reported
as mean 6 standard deviation.
RESULTS
Demographics. A total of 54 patients were evaluated. The
mean age was 65 6 10 years, with 74.1% men, and NYHA
functional classes distributed as follows: class I, 0%; class II,
22%; class III, 65%; and class IV, 13%. The cardiac disease
process included 70% with an ischemic cardiomyopathy,
with the remainder nonischemic dilated cardiomyopathies
subcategorized as idiopathic in 26%, hypertensive in 2%,
and alcoholic in 2%. The type of interventricular conduction
delay was left bundle branch block in 80%, right bundle
branch block in 7%, and nonspecific in 13%. The primary
indication for an ICD was symptomatic monomorphic
ventricular tachycardia (VT) in 43%, nonsustained VT
meeting the MADIT (Multicenter Automatic Defibrillator
Implantation Trial) criteria in 30%, ventricular fibrillation in
15%, and polymorphic VT in 9%, with 4% unreported (9).
Patients for analysis. Nine patients died before comple-
tion of both arms of the protocol, and one other withdrew
from the study. Two patients had fractures of the LV lead,
which were not repaired, and they were thus excluded from
analysis. Four patients have not completed the second phase
of evaluation; six have incomplete data sets related to the
second phase. Thus, from the original 54, there are 32
patients available for paired analysis. Episodes reported are
combined for both shocks and antitachycardia pacing
(ATP) because discrimination between the two modes of
tachycardia termination was not available. However, anti-
tachycardia schemes were not modified for either of the two
periods studied. All episodes included had electrogram
confirmation of a ventricular tachyarrhythmia.
Of the 32 completed patients, 13 (41%) received appro-
priate therapy for a ventricular tachyarrhythmia at least once
in the six-month monitoring period postimplant. Five
patients (16%) had at least one tachyarrhythmic episode
while programmed to BV pacing, whereas 11 (34%) had at
least one episode while programmed to no pacing (Table 1).
Three patients (9%) received therapy in both pacing periods,
two with BV pacing only. Thus, of those patients who
received ICD therapy at any time, 8 of 13 (62%) therapies
Abbreviations and Acronyms
ATP 5 antitachycardia pacing
BV 5 biventricular
HF 5 heart failure
ICD 5 implantable cardioverter defibrillator
LV 5 left ventricular
NYHA 5 New York Heart Association
VT 5 ventricular tachycardia
Figure 1. Postero-anterior radiograph of a patient with a Ventak CHF
ICD system. Note the standard dual-chamber transvenous leads as well as
two (one redundant) unipolar epicardial leads in the mid-lateral left
ventricle.
Table 1. Patient Distribution by Pacing Mode and Therapy
Delivery (n 5 32)
BV Pacing
Episodes
No
Episodes
No Pacing
Episodes 3 (9%) 8 (25%)
No Episodes 2 (6%) 19 (59%)
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occurred during the no-pacing period only, two (15%)
during BV pacing only, and three (23%) during both
periods. For individual patients receiving antitachycardia
therapy, the decrease in the ICD therapy noted in the BV
pacing mode was suggestive but did not achieve statistical
significance (p 5 0.058), although it did for antitachycardia
episodes (p 5 0.035).
Study end points. There were 20 therapy episodes in the 32
patients (0.6 6 2.1) during BV pacing, while there were 44
episodes (1.4 6 3.5) in the same patient population during no
pacing (Table 2). This difference was found to be statistically
significant (p 5 0.035). These findings persisted regardless of
pacing order (no pacing or VDD pacing) of the three-month
pacing periods. Period effect and treatment-period interaction
effects were found to be nonsignificant with t-tests.
It is interesting that there was no difference in number of
therapy episodes per patient for those who received therapy.
Of the five receiving therapy in BV mode, there were 4.0 6
4.1 antitachycardia episodes per patient versus 4.0 6 5.1
episodes per patient in the 11 patients in the no-pacing
mode. Thus, ICD therapy was less common in the BV
pacing mode, but if therapy was needed, patients in the BV
pacing mode required a similar number of treatment epi-
sodes as when therapy was required in the no-pacing mode.
DISCUSSION
Potential mechanisms. In patients serving as their own
controls, ICD therapy (both shocks and ATP) was less
common with BV pacing than with no pacing (actually,
pacing provided as a backup at 40 ppm). There are several
potential mechanisms for this diminution in the need for
tachyarrhythmia therapy: a decrease in ventricular conduc-
tion delays with BV pacing contributing to a decrease in
macro-reentry; avoidance of pause-dependent tachyarrhyth-
mias; and a decrease in plasma norepinephrine levels with
BV pacing as well as other effects of pacing on the
mechanism of arrhythmia induction (10). Research contin-
ues with respect to whether this diminution in ICD therapy
with BV pacing is also observed with transvenous LV leads
placed via the coronary sinus, as opposed to the epicardial
active fixation leads of the present study (11).
Although it is not reported here, improvement in ven-
tricular hemodynamic performance (and clinical HF symp-
toms) remains a probable contributing factor for the ob-
served prevention of the need for shock therapy with BV
pacing (5). As mentioned, several prior studies, both using
patients as concurrent controls and matched trials, have
shown that ICD therapy is less common when HF is
clinically compensated (1–3). The mechanism for this ob-
servation is not well understood, but it probably includes a
decrease in localized conduction delays as a result of
diminished ventricular chamber sizes.
Biventricular pacing without ICD backup. Although BV
pacing may not obviate the need for ICD therapy, it appears
to significantly diminish the number of appropriate ICD
therapy episodes (ATP and shocks). It has been postulated
that BV pacing can be applied without concomitant avail-
ability of ICD tachyarrhythmia therapy. We evaluated
preoperative clinical parameters in an attempt to determine
whether subsequent need for ICD therapy could be reliably
anticipated. Unfortunately, we could not determine such
predictive factors.
Study limitations. The Ventak CHF study was designed
to determine the safety and efficacy of BV pacing in the
treatment of HF in patients with indications for an ICD. In
our analysis, we find that this therapy may limit the need for
tachyarrhythmia treatment. However, it is an observed
retrospective finding and thus may represent a coincidental
or Type I error.
Although we postulate that improvement in HF contrib-
utes to the decreased need for tachyarrhythmia therapy, we
have no proof of the direct relationship of these findings.
Certainly, it is possible that other mechanisms may be
responsible. The insertion of multiple epicardial leads could
undoubtedly play a role in the generation or prevention of
Table 2. Number of Therapy Episodes in the 32 Data Pairs
During Each of the 3-Month BV (Biventricular) Pacing and
No-Pacing Periods
Patient
Number
Number of Episodes
BV
Pacing
No
Pacing
1 4 0
2 0 1
3 0 0
4 0 1
5 0 3
6 0 3
7 0 0
8 3 8
9 0 1
10 0 1
11 0 0
12 0 0
13 0 3
14 0 0
15 0 0
16 0 0
17 0 0
18 0 0
19 0 0
20 0 0
21 1 0
22 0 0
23 0 0
24 11 18
25 0 0
26 0 0
27 0 0
28 0 0
29 0 3
30 1 2
31 0 0
32 0 0
Mean 6 STD 0.6 6 2.1* 1.4 6 3.5*
*p 5 0.035.
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arrhythmias. For example, it has been shown that multisite
pacing in the atrium diminishes the incidence of certain
atrial arrhythmias (12). In addition, the current configura-
tion of the ICD lead system precluded comparison of right
ventricular pacing with the BV configuration, so the differ-
ences noted could be a function of dual-chamber right
ventricular pacing alone rather than BV pacing. Finally, the
study evaluated the potential benefit of BV pacing in a
three-month interval beginning one month after implanta-
tion. The permanence of arrhythmia modification with BV
pacing was not assessed. Despite the diminished antitachy-
cardia therapy observed, the mortality remained high for the
study participants. Presumably, this was related to the
selection requirements of patients with severe symptomatic
HF (78% NYHA classes III–IV).
Conclusions. In selected patients with standard ICD in-
dications who also have HF and an intraventricular conduc-
tion delay, ICD therapy (shocks and ATP) is less common
with BV pacing. The mechanism for this reduction of
ventricular arrhythmias is unclear, although it is presumed
to be caused, at least partly, by the improvement in LV
performance achieved with atrial-synchronous BV pacing.
Although BV pacing may not obviate the need for ICD
therapy, it appears to significantly diminish the number of
appropriate ICD therapy episodes (ATP and shocks). Fur-
ther study of the mechanism and clinical significance of this
interesting observation is necessary.
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